17,531 results on '"Interleukin 2"'
Search Results
2. Immunotherapy of Clear-Cell Renal-Cell Carcinoma.
- Author
-
Grigolo, Sophie and Filgueira, Luis
- Subjects
- *
COMBINATION drug therapy , *IMMUNOTHERAPY , *IMMUNOGLOBULINS , *RENAL cell carcinoma , *PROGRAMMED cell death 1 receptors , *IMMUNOLOGIC receptors , *AMINO acids , *IMMUNE checkpoint proteins , *IMMUNITY , *INTERLEUKINS - Abstract
Simple Summary: Immunotherapeutic synergy represents the cornerstone of the treatment intended for patients with clear-cell renal-cell carcinoma. In most cases, this type of cancer manifests its first symptoms at an advanced stage, thus compromising the use of local therapies such as surgery. This paper aims to describe immune checkpoint proteins, known to suppress an anti-cancer immune response, as well as their inhibitors. Interleukin-2, a cytokine used as a therapeutic option and implicated in the activation of the immune cells, is also discussed. This review further emphasizes the role of the immunotherapeutic combination, not only as an alternative to current treatments devised to counteract the progression and metastasis of ccRCC but also as a valid solution aimed at alleviating the limitations resulting from immune-based monotherapies. Clear-cell Renal-Cell Carcinoma (ccRCC) is the most common type of renal-cell carcinoma (RCC). In many cases, RCC patients manifest the first symptoms during the advanced stage of the disease. For this reason, immunotherapy appears to be one of the dominant treatments to achieve a resolution. In this review, we focus on the presentation of the main immune checkpoint proteins that act as negative regulators of immune responses, such as PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3, and their respective inhibitors. Interleukin-2, another potential component of the treatment of ccRCC patients, has also been covered. The synergy between several immunotherapies is one of the main aspects that unites the conclusions of research in recent years. To date, the combination of several immunotherapies enhances the efficacy of a monotherapy, which often manifests important limitations. Immunotherapy aimed at restoring the anti-cancer immune response in ccRCC, involved in the recognition and elimination of cancer cells, may also be a valid solution for many other types of immunogenic tumors that are diagnosed in the final stages. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Cloning and Expression of Human Interleukin 2 (IL-2) in E. coli and its Antitumor Activity.
- Author
-
Shafique, Qurrat ul Ain, Batool, Sana, Ashfaq, Hanfa, Tayyab, Asima, Gul, Roquyya, and Saleem, Mahjabeen
- Abstract
Interleukin 2, also known as T cell growth factor, brought a great revolution in the field of immunology. IL-2 is a pleiotropic cytokine and one of the cytokines that is approved by FDA for cancer immunotherapy particularly kidney and skin cancer. Interleukin-2 (IL-2) is a 4-helix-bundle type I cytokine possessing a cytokine receptor chain essential for the immune response. The current study presents a vector/host combination (pET28a(+)/IL-2) and optimization of expression in LB, TB and M9 media with varying concentrations of inducers (IPTG and lactose) and post induction time. Maximum expression of IL-2 was achieved in LB with 0.5 mM IPTG for 6 hours post induction time. A denaturing purification scheme (Immobilized metal affinity chromatography) was employed for the purification of IL-2. The refolding of the purified IL-2 was achieved by stepwise dialysis method using urea gradient (8M-0M). Human IL-2 was recovered from 1 litre culture to a purity level of ~95%. In vitro cytotoxic potential of IL-2 on HepG-2 and MCF-7 cell lines revealed that it possess sufficient cytotoxic potential and can inhibit the growth of these cell lines directly. Thus, refolded IL-2 had activity identical to that of authentic IL-2 and enhanced the anti-tumor activity of HepG-2 as compared to MCF-7 cells. These conclusions suggest the potential use of the refolded cytokine as immunotherapeutic agent for treatment of hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. IL2RA rs2104286 and IL2 rs2069762 polymorphisms may be associated with bipolar disorder and its clinical findings.
- Author
-
Pehlivan, Sacide, Aytac, Hasan Mervan, Nursal, Ayse Feyda, Tuncel, Fatima Ceren, and Pehlivan, Mustafa
- Subjects
- *
RESTRICTION fragment length polymorphisms , *BIPOLAR disorder , *TURKS - Abstract
Study results supported that immuno-inflammatory pathways in the brain and environment contribute to the etiopathogenesis of bipolar disorder (BD), a chronic affective disease. Our study aimed to assess the relationship between BD risk and interleukin 2 (IL2) and interleukin 2 receptor subunit alpha (IL2RA) variants in a Turkish population. Genomic DNA from 86 diagnosed BD patients and 100 healthy blood donors was extracted. IL2RA rs2104286, IL2 rs2069762, and IL2 rs2069763 variants were genotyped using the polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) method. It was compared to the relationship between the genotype distributions of these variants and clinical characteristics. Results were evaluated statistically. A statistically significant difference in the genotype distribution of the IL2RA rs2104286 variant was found between patients and controls. There was no GG genotype in the patient group. The IL2RA rs2104286 AA genotype was more common in the patient group than the controls, and the AG genotype was higher in the controls compared to the patients (p = 0.001, p = 0.001, respectively). The IL2 rs2069762 and IL2 rs2069763 genotype distributions did not differ between the patient and control groups (p > 0.05). We found that the clinical global impression severity (CGI-S) score was higher in those with IL2 rs2069762 TG and GG genotypes. In this study, we showed for the first time that the genotype distribution of IL2RA rs2104286 and IL2 rs2069762 is associated with BD susceptibility and CGI-S score in a Turkish population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Low-dose interleukin 2 antidepressant potentiation in unipolar and bipolar depression: Safety, efficacy, and immunological biomarkers.
- Author
-
Poletti, Sara, Zanardi, Raffaella, Mandelli, Alessandra, Aggio, Veronica, Finardi, Annamaria, Lorenzi, Cristina, Borsellino, Giovanna, Carminati, Matteo, Manfredi, Elena, Tomasi, Enrico, Spadini, Sara, Colombo, Cristina, Drexhage, Hemmo A., Furlan, Roberto, and Benedetti, Francesco
- Subjects
- *
MENTAL depression , *INTERLEUKIN-2 , *BIPOLAR disorder , *DYSTHYMIC disorder , *ANTIDEPRESSANTS , *BODY dysmorphic disorder , *T cells - Abstract
• Immune-inflammatory mechanisms are promising targets for antidepressant pharmacology. • In a randomized controlled trial low-dose IL-2 significantly improved antidepressant response. • IL-2 rapidly expanded the population of Treg, Th2, and Naive CD4+/CD8 + immune cell counts. • Strengthening in the T cell system predicted antidepressant response. Immune-inflammatory mechanisms are promising targets for antidepressant pharmacology. Immune cell abnormalities have been reported in mood disorders showing a partial T cell defect. Following this line of reasoning we defined an antidepressant potentiation treatment with add-on low-dose interleukin 2 (IL-2). IL-2 is a T-cell growth factor which has proven anti-inflammatory efficacy in autoimmune conditions, increasing thymic production of naïve CD4 + T cells, and possibly correcting the partial T cell defect observed in mood disorders. We performed a single-center, randomised, double-blind, placebo-controlled phase II trial evaluating the safety, clinical efficacy and biological responses of low-dose IL-2 in depressed patients with major depressive (MDD) or bipolar disorder (BD). 36 consecutively recruited inpatients at the Mood Disorder Unit were randomised in a 2:1 ratio to receive either aldesleukin (12 MDD and 12 BD) or placebo (6 MDD and 6 BD). Active treatment significantly potentiated antidepressant response to ongoing SSRI/SNRI treatment in both diagnostic groups, and expanded the population of T regulatory, T helper 2, and percentage of Naive CD4+/CD8 + immune cells. Changes in cell frequences were rapidly induced in the first five days of treatment, and predicted the later improvement of depression severity. No serious adverse effect was observed. This is the first randomised control trial (RCT) evidence supporting the hypothesis that treatment to strengthen the T cell system could be a successful way to correct the immuno-inflammatory abnormalities associated with mood disorders, and potentiate antidepressant response. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. The effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models
- Author
-
Zilong Wang, Zhicheng Liu, Jiarui Zheng, Linxiang Huang, Rui Jin, Xiaoxiao Wang, Dongbo Chen, Yandi Xie, and Bo Feng
- Subjects
Primary biliary cholangitis ,Interleukin 2 ,Treg cells ,Th17 cells ,Mouse model ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background/aims Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The imbalance of Th17/Treg cells has been reported in PBC patients. Low-dose IL-2 can alleviate disease severity through modulating CD4 + T cell subsets in patients with autoimmune diseases. Hence, the present study aimed to examine the effects and mechanism of low-dose IL-2 in PBC mouse models. Methods PBC models were induced in female C57BL/6 mice by two immunizations with 2OA-BSA at two-week intervals, and poly I: C every three days. PBC mouse models were divided into the IL-2 treated and untreated groups and low-dose IL-2 was injected at three different time points. Th17 and Tregs were analyzed by flow cytometry, and the related cytokines were analyzed by ELISA. Liver histopathology was examined by H&E and immunohistochemical staining. Results Twelve weeks after modeling, the serum AMA was positive and the ALP was significantly increased in PBC mouse models (P
- Published
- 2024
- Full Text
- View/download PDF
7. The effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models.
- Author
-
Wang, Zilong, Liu, Zhicheng, Zheng, Jiarui, Huang, Linxiang, Jin, Rui, Wang, Xiaoxiao, Chen, Dongbo, Xie, Yandi, and Feng, Bo
- Subjects
- *
LABORATORY mice , *T helper cells , *ANIMAL disease models , *REGULATORY T cells , *LIVER cells - Abstract
Background/aims: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The imbalance of Th17/Treg cells has been reported in PBC patients. Low-dose IL-2 can alleviate disease severity through modulating CD4 + T cell subsets in patients with autoimmune diseases. Hence, the present study aimed to examine the effects and mechanism of low-dose IL-2 in PBC mouse models. Methods: PBC models were induced in female C57BL/6 mice by two immunizations with 2OA-BSA at two-week intervals, and poly I: C every three days. PBC mouse models were divided into the IL-2 treated and untreated groups and low-dose IL-2 was injected at three different time points. Th17 and Tregs were analyzed by flow cytometry, and the related cytokines were analyzed by ELISA. Liver histopathology was examined by H&E and immunohistochemical staining. Results: Twelve weeks after modeling, the serum AMA was positive and the ALP was significantly increased in PBC mouse models (P<0.05). The pathology showed lymphocyte infiltration in the portal area, damage, and reactive proliferation of the small bile duct (P<0.05). The flow cytometric showed the imbalance of Th17/Treg cells in the liver of PBC mouse models, with decreased Treg cells, increased Th17 cells, and Th17/Treg ratio (P < 0.05). After the low-dose IL-2 intervention, biochemical index and liver pathologies showed improvement at 12 weeks. Besides, the imbalance of Th17 and Treg cells recovered. Public database mining showed that Th17 cell differentiation may contribute to poor response in PBC patients. Conclusion: Low-dose IL-2 can significantly improve liver biochemistry and pathology by reversing the imbalance of Th17 and Treg cells, suggesting that it may be a potential therapeutic target for PBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. The combination of IL-2 nanoparticles and Palbociclib enhances the anti-tumor immune response for colon cancer therapy.
- Author
-
Di Wang, Xiaoshuang Wang, Yingyu Zhang, Le Yu, Jing An, Xiaodong Wang, Yue Huang, and Xuemei Han
- Subjects
COLON cancer ,IMMUNE response ,CANCER treatment ,REGULATORY T cells ,CYCLIN-dependent kinase inhibitors - Abstract
Immunotherapy of tumors plays a pivotal role in the current treatment of cancer. While interleukin 2 (IL-2) demonstrated its efficacy as an immunotherapeutic drug in the early days, its short blood circulation time poses challenges in maintaining effective therapeutic concentrations. Additionally, IL-2's activation of regulatory T cells can counteract its anti-cancer effects. Therefore, the primary goal of this study was to formulate IL-2-carrying nanoparticles via boronnitrogen coordination between methoxy poly (ethylene glycol) block poly-[(N- 2-hydroxyethyl)-aspartamide]phenylboronic acid (mPEG-b-PHEA-PBA, P-PBA) and poly (L-lysine) (PLL). These nanoparticles are intended to be used in combination with CDK4/6 inhibitors to address the short blood circulation time of IL-2, reduce its immunosuppressive effects, and enhance the overall immune response. The envisaged outcome is a sustained and potent therapeutic effect, offering a novel and promising combination therapy strategy for tumor immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Predicting anti-TNF treatment response in rheumatoid arthritis: An artificial intelligence-driven model using cytokine profile and routine clinical practice parameters
- Author
-
Juan Luis Valdivieso Shephard, Enrique Josue Alvarez Robles, Carmen Cámara Hijón, Borja Hernandez Breijo, Marta Novella-Navarro, Patricia Bogas Schay, Ricardo Cuesta de la Cámara, Alejandro Balsa Criado, Eduardo López Granados, and Chamaida Plasencia Rodríguez
- Subjects
Rheumatoid arthritis ,Cytokines ,Artificial intelligence ,Anti-TNF response prediction ,Interleukin 2 ,Interleukin 6 ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Introduction: Rheumatoid arthritis (RA) is a heterogeneous disease in which therapeutic strategies used have evolved dramatically. Despite significant progress in treatment strategies such as the development of anti-TNF drugs, it is still not possible to differentiate those patients who will respond from who will not. This can lead to effective-treatment delays and unnecessary costs. The aim of this study was to utilize a profile of the patient's characteristics, clinical parameters, immune status (cytokine profile) and artificial intelligence to assess the feasibility of developing a tool that could allow us to predict which patients will respond to treatment with anti-TNF drugs. Methods: This study included 38 patients with RA from the RA-Paz cohort. Clinical activity was measured at baseline and after 6 months of treatment. The cytokines measured before the start of anti-TNF treatment were IL-1, IL-12, IL-10, IL-2, IL-4, IFNg, TNFa, and IL-6. Statistical analyses were performed using the Wilcoxon-Rank-Sum Test and the Benjamini-Hochberg method. The predictive model viability was explored using the 5-fold cross-validation scheme in order to train the logistic regression models. Results: Statistically significant differences were found in parameters such as IL-6, IL-2, CRP and DAS-ESR. The predictive model performed to an acceptable level in correctly classifying patients (ROC-AUC 0.804167 to 0.891667), suggesting that it would be possible to develop a clinical classification tool. Conclusions: Using a combination of parameters such as IL-6, IL-2, CRP and DAS-ESR, it was possible to develop a predictive model that can acceptably discriminate between remitters and non-remitters. However, this model needs to be replicated in a larger cohort to confirm these findings.
- Published
- 2024
- Full Text
- View/download PDF
10. Immunotherapy of Clear-Cell Renal-Cell Carcinoma
- Author
-
Sophie Grigolo and Luis Filgueira
- Subjects
clear-cell renal-cell carcinoma ,immune checkpoint proteins ,interleukin 2 ,immunotherapy combinations ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Clear-cell Renal-Cell Carcinoma (ccRCC) is the most common type of renal-cell carcinoma (RCC). In many cases, RCC patients manifest the first symptoms during the advanced stage of the disease. For this reason, immunotherapy appears to be one of the dominant treatments to achieve a resolution. In this review, we focus on the presentation of the main immune checkpoint proteins that act as negative regulators of immune responses, such as PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3, and their respective inhibitors. Interleukin-2, another potential component of the treatment of ccRCC patients, has also been covered. The synergy between several immunotherapies is one of the main aspects that unites the conclusions of research in recent years. To date, the combination of several immunotherapies enhances the efficacy of a monotherapy, which often manifests important limitations. Immunotherapy aimed at restoring the anti-cancer immune response in ccRCC, involved in the recognition and elimination of cancer cells, may also be a valid solution for many other types of immunogenic tumors that are diagnosed in the final stages.
- Published
- 2024
- Full Text
- View/download PDF
11. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo
- Author
-
Fernandez, Manuel F, Qiao, Guilin, Tulla, Kiara, Prabhakar, Bellur S, and Maker, Ajay V
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Vaccine Related ,Immunization ,Colo-Rectal Cancer ,Cancer ,Digestive Diseases ,Animals ,CD8-Positive T-Lymphocytes ,Cell Line ,Tumor ,Colonic Neoplasms ,Disease Models ,Animal ,Female ,Gene Expression Regulation ,Neoplastic ,Humans ,Immunologic Memory ,Immunotherapy ,Injections ,Intralesional ,Interleukin-2 ,Liposomes ,Lymphocytes ,Tumor-Infiltrating ,Mice ,Recombinant Proteins ,Tumor Microenvironment ,Tumor Necrosis Factor Ligand Superfamily Member 14 ,CD8 ,Colon cancer ,Effector memory ,Interleukin 2 ,LIGHT ,Liposomal ,Memory ,Microsatellite stable ,T cells ,TNFSF14 ,Clinical Sciences ,Surgery ,Clinical sciences - Abstract
BackgroundThe generation of long-term durable tumor immunity and prolonged disease-free survival depends on the ability to generate and support CD8+ central memory T-cells. Microsatellite-stable colon cancer is resistant to currently available immunotherapies; thus, development of novel mechanisms to increase both lymphocyte infiltration and central memory formation are needed to improve outcomes in these patients. We have previously demonstrated that both interleukin-2 (IL-2) and LIGHT (TNFSF14) independently enhance antitumor immune responses and hypothesize that combination immunotherapy may increase the CD8+ central memory T-cell response.MethodsMurine colorectal cancer tumors were established in syngeneic mice. Tumors were treated with control, soluble, or liposomal IL-2 at established intervals. A subset of animal tumors overexpressed tumor necrosis superfamily factor LIGHT (TNFSF14). Peripheral blood, splenic, and tumor-infiltrating lymphocytes were isolated for phenotypic studies and flow cytometry.ResultsTumors exposed to a combination of LIGHT and IL-2 experienced a decrease in tumor size compared with IL-2 alone that was not demonstrated in wild-type tumors or between other treatment groups. Combination exposure also increased splenic central memory CD8+ cells compared with IL-2 administration alone, while not increasing tumor-infiltrating lymphocytes. In the periphery, the combination enhanced levels of circulating CD8 T-cells and central memory T-cells, while also increasing circulating T-regulatory cells.ConclusionsCombination of IL-2, whether soluble or liposomal, with exposure to LIGHT results in increased CD8+ central memory cells in the spleen and periphery. New combination immunotherapy strategies that support both effector and memory T-cell functions are critical to enhancing durable antitumor responses and warrant further investigation.
- Published
- 2021
12. The decreased of peripheral blood natural killer cell is associated with serum IL-2 level in the renal tubular acidosis in patients with primary sjogren’s syndrome
- Author
-
Liyun Cheng, Lu Liu, Ronghui Su, Huanhuan Yan, Xiaoyu Zi, Chong Gao, Xiaofeng Li, and Caihong Wang
- Subjects
Primary Sjogren’s Syndrome ,Renal tubular acidosis ,Interleukin 2 ,Natural killer cells ,Regulatory T cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background Primary Sjogren’s Syndrome (pSS) is a lymphoproliferative disease with autoimmune characteristics, which is characterized by lymphocyte infiltration of exocrine glands and involvement and dysfunction of extraglandular organs. Renal tubular acidosis (RTA) is a common renal involvement in pSS. This study investigated the phenotypic characteristics of peripheral blood lymphocyte subsets and cytokines in pSS patients complicated with RTA (pSS-RTA). Method This retrospective study included 25 pSS patients complicated with RTA and 54 pSS patients without RTA (pSS-no-RTA). To examine the level of peripheral lymphocytes subsets, flow cytometry analysis was used. The level of serum cytokines were detected by flow cytometry bead array(CBA). The influencing factors related to the occurrence of pSS-RTA were identified through logistic regression analyze. Results The absolute number of CD4 + T cells and Th2 cells in peripheral blood were decreased in pSS-RTA patients than pSS-no-RTA patients. Moreover, the absolute number of NK cells and Treg cells were also decreased in pSS-RTA patients than pSS-no-RTA. The level of serum IL-2 was higher in pSS-RTA patients than pSS-no-RTA patients, and is negatively correlated with the number of NK cells, the number and percentage of Th17 cells, and Th17/Treg. Serum IL-2 level is also correlated with various cytokines. Multivariate logistic analysis proved that elevated ESR and ALP were risk factors for pSS complicated with RTA, while Treg was a protective factor. Conclusion The increase of serum IL-2 level and the decrease of peripheral blood NK cells and Treg cells may be the immune mechanism of the development of pSS-RTA disease.
- Published
- 2023
- Full Text
- View/download PDF
13. Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.
- Author
-
Wang, Hongbin, Borlongan, Mia, Hemminki, Akseli, Basnet, Saru, Sah, Naresh, Kaufman, Howard L., Rabkin, Samuel D., and Saha, Dipongkor
- Subjects
- *
GENETIC vectors , *KILLER cells , *CYTOTOXIC T cells , *NEWCASTLE disease , *RENAL cell carcinoma , *IMMUNOTHERAPY , *T cells - Abstract
Interleukin 2 (IL-2) plays a crucial role in T cell growth and survival, enhancing the cytotoxic activity of natural killer and cytotoxic T cells and thus functioning as a versatile master proinflammatory anticancer cytokine. The FDA has approved IL-2 cytokine therapy for the treatment of metastatic melanoma and metastatic renal cell carcinoma. However, IL-2 therapy has significant constraints, including a short serum half-life, low tumor accumulation, and life-threatening toxicities associated with high doses. Oncolytic viruses (OVs) offer a promising option for cancer immunotherapy, selectively targeting and destroying cancer cells while sparing healthy cells. Numerous studies have demonstrated the successful delivery of IL-2 to the tumor microenvironment without compromising safety using OVs such as vaccinia, Sendai, parvo, Newcastle disease, tanapox, and adenoviruses. Additionally, by engineering OVs to coexpress IL-2 with other anticancer transgenes, the immune properties of IL-2 can be further enhanced. Preclinical and clinical studies have shown promising antitumor effects of IL-2-expressing viral vectors, either alone or in combination with other anticancer therapies. This review summarizes the therapeutic potential of IL-2-expressing viral vectors and their antitumor mechanisms of action. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. An optimized cultivation method for future in vivo application of γδ T cells.
- Author
-
Bold, Anna, Gross, Heike, Holzmann, Elisabeth, Knop, Stefan, Hoeres, Timm, and Wilhelm, Martin
- Subjects
T cells ,ANTIBODY-dependent cell cytotoxicity ,T cell receptors ,GRAFT versus host reaction ,MAJOR histocompatibility complex ,CURRENT good manufacturing practices ,CYTOTOXIC T cells - Abstract
γδ T cells, with their properties of both the innate and acquired immune systems, are suitable candidates for cellular immunotherapy in cancer. Because of their non-major histocompatibility complex (MHC) binding T cell receptor, allogenic transfer is feasible without relevant graft versus host reactions. In recent years, much experience has been gained with ex vivo expansion and stimulation of γδ T cells using bisphosphonates and Interleukin 2. Unfortunately, many current stimulation protocols are based on the use of xenogenic materials and other potentially hazardous supplements, which conflicts with basic principles of Good Manufacturing Practice (GMP). Adherence to the concept and current guidelines of GMP is state of the art for production of Advanced Therapy Medicinal Products (ATMP) like cell therapeutics and a necessity for clinical use under a regulatory perspective. In this study, we developed a new stimulation protocol that induces a marked increase of γδ T cell counts and allows for an easier transition from research to clinical applications with minimized regulatory workload. It reliably leads to a cell product with a purity of more than 90% γδ T cells and improved in vitro anti-tumor activity compared to our previous standard procedure. Furthermore, by investigating correlations between properties of unstimulated γδ T cells and proliferation rate as well as degranulation ability of stimulated γδ T cells, we can draw conclusions about suitable donors. Finally, we examined if expansion can be improved by pulsing zoledronate and/or using Interleukin 15 with or without Interleukin 2. Significant improvements can be achieved with respect to intrinsic and antibody-dependent cell-mediated cytotoxicity. Our results demonstrate that the stimulation protocol presented here leads to an improved γδ T cell product for future clinical applications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
- Author
-
Pakola, Santeri, Quixabeira, Dafne C. A., Kudling, Tatiana V., Clubb, James H. A., Grönberg-Vähä-Koskela, Susanna, Basnet, Saru, Jirovec, Elise, Arias, Victor, Haybout, Lyna, Heiniö, Camilla, Santos, Joao M., Cervera-Carrascon, Victor, Havunen, Riikka, Anttila, Marjukka, and Hemminki, Akseli
- Subjects
ADENOVIRUS diseases ,PACLITAXEL ,REGULATORY T cells ,TUMOR-infiltrating immune cells ,FIBROBLASTS ,CANCER chemotherapy ,ADENOVIRUSES - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only curative treatment for PDAC is surgery, but most patients are diagnosed with metastatic disease and thus outside the scope of surgery. The majority of metastatic patients receive chemotherapy, but responses are limited. New therapeutics are thus urgently needed for PDAC. One major limitation in treating PDAC has been the highly immunosuppressive tumor microenvironment (TME) which inhibits anti-cancer immune responses. We have constructed an oncolytic adenovirus coding for a variant the interleukin 2 molecule, Ad5/3-E2Fd24-vIL2 (also known as TILT-452, and "vIL-2 virus"), with preferential binding to IL-2 receptors on the surface of effector lymphocytes over T regulatory cells (T regs). In the present study this virus was evaluated in combination with nabpaclitaxel and gemcitabine chemotherapy in Panc02 mouse model. Ad5/3-E2Fd24-vIL2 showed marked PDAC cell killing in vitro, alongside induction of mitotic slippage and immunogenic cell death in PDAC cell lines, when combined with chemotherapy. Increased survival was seen in vivo with 80% of animals surviving long term, when compared to chemotherapy alone. Moreover, combination therapy mediated enhanced tumor growth control, without observable toxicities in internal organs or external features. Survival and tumor control benefits were associated with activation of tumor infiltrating immune cells, downregulation of inhibitory signals, change in fibroblast populations in the tumors and changes in intratumoral cytokines, with increased chemokine amounts (CCL2, CCL3, CCL4) and anti-tumor cytokines (IFN-γ and TNFα). Furthermore, vIL-2 virus in combination with chemotherapy efficiently induced tumor protection upon rechallenge, that was extended to a previously non-encountered cancer cell line. In conclusion, Ad5/3-E2F-d24-vIL2 is a promising immunotherapy candidate when combined with nab-paclitaxel and gemcitabine. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. IL-2-loaded Polypeptide Nanoparticles for Enhanced Anti-cancer Immunotherapy.
- Author
-
Wang, Xiao-Shuang, Zheng, Zhao-Shi, Zheng, Meng-Fei, Wang, Di, Zhang, Hong-Lei, Zhang, Zhen-Qian, Liu, Zhi-Lin, Tang, Zhao-Hui, and Han, Xue-Mei
- Subjects
- *
POLYPEPTIDES , *T cells , *REACTIVE oxygen species , *ETHYLENE glycol , *IMMUNOTHERAPY , *NANOPARTICLES - Abstract
Interleukin 2 (IL-2) is widely used as an active immunotherapeutic agent in clinical metastatic cancers. However, its therapeutic concentrations do not last long due to its short half-life. Thus, only a transient proliferation of the anti-cancer CD8+ T cells can be achieved, resulting in poor efficacy. Therefore, the aim of this work was to create a system that promotes CD8+ T cell proliferation at the tumor site using IL-2 persistently present and activates an anti-cancer immune response. This goal was achieved by the design of the IL-2-loaded polypeptide nanoparticles (P-IL-2) where methoxy poly(ethylene glycol) block poly-[(N-2-hydroxyethyl)-aspartamide] phenylboronic acid was used to encapsulate IL-2 through boron-nitrogen coordination with poly(L-lysine). P-IL-2 significantly prolonged the circulation time of IL-2 and achieved a selective drug release at the tumor site in the presence of high levels of reactive oxygen species, thus activating an anti-cancer immune response and exerting a better anti-cancer effect. The half-life of P-IL-2 was 3.15-fold higher than that of IL-2, and the quantity of CD8+ T cells after using P-IL-2 was 1.89-fold higher than that after using IL-2. In addition, the combination of P-IL-2 and anti-CTLA-4 monoclonal antibody resulted in an enhanced immune activation. Hence, this work provides a new approach to improve the efficacy of IL-2 in anti-cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. An optimized cultivation method for future in vivo application of γδ T cells
- Author
-
Anna Bold, Heike Gross, Elisabeth Holzmann, Stefan Knop, Timm Hoeres, and Martin Wilhelm
- Subjects
γδ T cells ,Vγ9Vδ2 T cells ,cellular immunotherapy ,zoledronate ,interleukin 2 ,interleukin 15 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
γδ T cells, with their properties of both the innate and acquired immune systems, are suitable candidates for cellular immunotherapy in cancer. Because of their non-major histocompatibility complex (MHC) binding T cell receptor, allogenic transfer is feasible without relevant graft versus host reactions. In recent years, much experience has been gained with ex vivo expansion and stimulation of γδ T cells using bisphosphonates and Interleukin 2. Unfortunately, many current stimulation protocols are based on the use of xenogenic materials and other potentially hazardous supplements, which conflicts with basic principles of Good Manufacturing Practice (GMP). Adherence to the concept and current guidelines of GMP is state of the art for production of Advanced Therapy Medicinal Products (ATMP) like cell therapeutics and a necessity for clinical use under a regulatory perspective. In this study, we developed a new stimulation protocol that induces a marked increase of γδ T cell counts and allows for an easier transition from research to clinical applications with minimized regulatory workload. It reliably leads to a cell product with a purity of more than 90% γδ T cells and improved in vitro anti-tumor activity compared to our previous standard procedure. Furthermore, by investigating correlations between properties of unstimulated γδ T cells and proliferation rate as well as degranulation ability of stimulated γδ T cells, we can draw conclusions about suitable donors. Finally, we examined if expansion can be improved by pulsing zoledronate and/or using Interleukin 15 with or without Interleukin 2. Significant improvements can be achieved with respect to intrinsic and antibody-dependent cell-mediated cytotoxicity. Our results demonstrate that the stimulation protocol presented here leads to an improved γδ T cell product for future clinical applications.
- Published
- 2023
- Full Text
- View/download PDF
18. An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
- Author
-
Santeri Pakola, Dafne C. A. Quixabeira, Tatiana V. Kudling, James H. A. Clubb, Susanna Grönberg-Vähä-Koskela, Saru Basnet, Elise Jirovec, Victor Arias, Lyna Haybout, Camilla Heiniö, Joao M. Santos, Victor Cervera-Carrascon, Riikka Havunen, Marjukka Anttila, and Akseli Hemminki
- Subjects
oncolytic virus ,immunotherapy ,chemotherapy ,interleukin 2 ,adenovirus ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly treatment-resistant cancer. Currently, the only curative treatment for PDAC is surgery, but most patients are diagnosed with metastatic disease and thus outside the scope of surgery. The majority of metastatic patients receive chemotherapy, but responses are limited. New therapeutics are thus urgently needed for PDAC. One major limitation in treating PDAC has been the highly immunosuppressive tumor microenvironment (TME) which inhibits anti-cancer immune responses. We have constructed an oncolytic adenovirus coding for a variant the interleukin 2 molecule, Ad5/3-E2F-d24-vIL2 (also known as TILT-452, and “vIL-2 virus”), with preferential binding to IL-2 receptors on the surface of effector lymphocytes over T regulatory cells (T regs). In the present study this virus was evaluated in combination with nab-paclitaxel and gemcitabine chemotherapy in Panc02 mouse model. Ad5/3-E2F-d24-vIL2 showed marked PDAC cell killing in vitro, alongside induction of mitotic slippage and immunogenic cell death in PDAC cell lines, when combined with chemotherapy. Increased survival was seen in vivo with 80% of animals surviving long term, when compared to chemotherapy alone. Moreover, combination therapy mediated enhanced tumor growth control, without observable toxicities in internal organs or external features. Survival and tumor control benefits were associated with activation of tumor infiltrating immune cells, downregulation of inhibitory signals, change in fibroblast populations in the tumors and changes in intratumoral cytokines, with increased chemokine amounts (CCL2, CCL3, CCL4) and anti-tumor cytokines (IFN-γ and TNFα). Furthermore, vIL-2 virus in combination with chemotherapy efficiently induced tumor protection upon rechallenge, that was extended to a previously non-encountered cancer cell line. In conclusion, Ad5/3-E2F-d24-vIL2 is a promising immunotherapy candidate when combined with nab-paclitaxel and gemcitabine.
- Published
- 2023
- Full Text
- View/download PDF
19. The decreased of peripheral blood natural killer cell is associated with serum IL-2 level in the renal tubular acidosis in patients with primary sjogren's syndrome.
- Author
-
Cheng, Liyun, Liu, Lu, Su, Ronghui, Yan, Huanhuan, Zi, Xiaoyu, Gao, Chong, Li, Xiaofeng, and Wang, Caihong
- Subjects
- *
KILLER cells , *SJOGREN'S syndrome , *RENAL tubular transport disorders , *REGULATORY T cells , *LYMPHOCYTE subsets , *TH2 cells - Abstract
Background: Primary Sjogren's Syndrome (pSS) is a lymphoproliferative disease with autoimmune characteristics, which is characterized by lymphocyte infiltration of exocrine glands and involvement and dysfunction of extraglandular organs. Renal tubular acidosis (RTA) is a common renal involvement in pSS. This study investigated the phenotypic characteristics of peripheral blood lymphocyte subsets and cytokines in pSS patients complicated with RTA (pSS-RTA). Method: This retrospective study included 25 pSS patients complicated with RTA and 54 pSS patients without RTA (pSS-no-RTA). To examine the level of peripheral lymphocytes subsets, flow cytometry analysis was used. The level of serum cytokines were detected by flow cytometry bead array(CBA). The influencing factors related to the occurrence of pSS-RTA were identified through logistic regression analyze. Results: The absolute number of CD4 + T cells and Th2 cells in peripheral blood were decreased in pSS-RTA patients than pSS-no-RTA patients. Moreover, the absolute number of NK cells and Treg cells were also decreased in pSS-RTA patients than pSS-no-RTA. The level of serum IL-2 was higher in pSS-RTA patients than pSS-no-RTA patients, and is negatively correlated with the number of NK cells, the number and percentage of Th17 cells, and Th17/Treg. Serum IL-2 level is also correlated with various cytokines. Multivariate logistic analysis proved that elevated ESR and ALP were risk factors for pSS complicated with RTA, while Treg was a protective factor. Conclusion: The increase of serum IL-2 level and the decrease of peripheral blood NK cells and Treg cells may be the immune mechanism of the development of pSS-RTA disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG.
- Author
-
Vidovic, Dejan, Helyer, Lucy Kathryn, Pasternak, Sylvia, and Giacomantonio, Carman Anthony
- Subjects
BCG immunotherapy ,METASTASIS ,OVERALL survival ,LANDSCAPE changes ,DISEASE progression ,MELANOMA - Abstract
Cutaneous melanoma is relatively common with increasing incidence and significant mortality. While the mainstay of therapy is surgical, patients with stage III and IV disease fare poorer than those with early-stage disease and often benefit from adjuvant therapies. While systemic immunotherapy has changed the landscape of melanoma treatment, for some patients systemic toxicities related to these treatments prohibit successful administration or completion of therapy. Moreover, it is becoming increasingly evident that nodal, regional, and in-transit disease appears to be resistant to systemic immunotherapy relative to responses observed in distant metastatic disease sites. In this scenario, intralesional immunotherapies may offer benefit. In this case series, we describe the use of intralesional IL-2 and BCG at our institution in ten patients with in-transit plus or minus distant cutaneous metastatic melanoma over the last twelve years. All patients received intralesional IL2 and BCG. Both treatments were very well tolerated with only grade 1/2 adverse events. In our cohort, complete clinical response was 60% (6/10), progressive disease in 20% (2/10), and no response in 20% (2/10) of patients. The overall response rate (ORR) was 70%. The median overall survival was 35.5 months and mean overall survival 43 months in this cohort. Herein we further highlight the clinical, histopathological, and radiological course of two complete responders, showing evidence of an abscopal effect with resolution of distant untreated metastasis. Together, this limited data supports the safe and effective use of intralesional IL2 and BCG for the treatment of metastatic or in-transit melanoma in this challenging patient cohort. To our knowledge, this is the first formal study to report on this combination therapy for the treatment of melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Molecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain.
- Author
-
Lemaitre, Pierre, Tareen, Samar HK, Pasciuto, Emanuela, Mascali, Loriana, Martirosyan, Araks, Callaerts‐Vegh, Zsuzsanna, Poovathingal, Suresh, Dooley, James, Holt, Matthew G, Yshii, Lidia, and Liston, Adrian
- Abstract
Cognitive decline is a common pathological outcome during aging, with an ill‐defined molecular and cellular basis. In recent years, the concept of inflammaging, defined as a low‐grade inflammation increasing with age, has emerged. Infiltrating T cells accumulate in the brain with age and may contribute to the amplification of inflammatory cascades and disruptions to the neurogenic niche observed with age. Recently, a small resident population of regulatory T cells has been identified in the brain, and the capacity of IL2‐mediated expansion of this population to counter neuroinflammatory disease has been demonstrated. Here, we test a brain‐specific IL2 delivery system for the prevention of neurological decline in aging mice. We identify the molecular hallmarks of aging in the brain glial compartments and identify partial restoration of this signature through IL2 treatment. At a behavioral level, brain IL2 delivery prevented the age‐induced defect in spatial learning, without improving the general decline in motor skill or arousal. These results identify immune modulation as a potential path to preserving cognitive function for healthy aging. Synopsis: Delivery of interleukin 2 into the brain via a blood–brain barrier crossing AAV vector prevents cognitive decline in the aging mice. A gene delivery system uses an AAV‐based viral vector coupled with an astrocyte‐specific promoter to drive the expression of the anti‐inflammatory cytokine interleukin 2 in the brain of aged mice.At a molecular level, brain‐specific expression of IL2 in aged mice partially reverted the transcriptional signature of aged glial cells to the baseline state of young glial cells.At a cognitive level, brain‐specific expression of IL2 in aged mice partially restored the spatial learning decline, without improving the general decline in motor skill or arousal. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Recalcitrant lupus miliaris disseminatus faciei improved by cyclosporine monotherapy
- Author
-
Hyeok-Jin Kwon, MD, Kyung-Deok Park, MD, Dong-Wha Yoo, MD, Jeong-Wan Seo, MD, Ki-Ho Kim, MD, PhD, and Jung-Ho Yoon, MD
- Subjects
cyclosporine ,interleukin 2 ,lupus miliaris disseminatus faciei ,type 1 immunity ,Dermatology ,RL1-803 - Published
- 2022
- Full Text
- View/download PDF
23. Effectiveness of gel formulation of capa leaf (Blumea balsamifera L.) on wound healing in white rats
- Author
-
Masyudi Masyudi, Muhammad Hanafiah, Said Usman, and Marlina Marlina
- Subjects
fibroblast ,interleukin 2 ,propylene glycol ,wound healing ,Animal culture ,SF1-1100 ,Veterinary medicine ,SF600-1100 - Abstract
Background and Aim: The capa plant (Blumea balsamifera L.) has been widely used as a traditional herbal medicine in many parts of the world, including South Aceh, Indonesia. It is generally used for wound healing due to its antibacterial and anti-inflammatory properties. However, it is only available as extract or oil, and no gel formulation exists so far. Thus, in this study, we formulated the extract into a pharmaceutical gel and investigated its effectiveness in healing incision wounds in white rats (Rattus norvegicus). Materials and Methods: We collected B. balsamifera leaf samples from Gunongpulo village, South Aceh, Indonesia. We then produced leaf extract through maceration and formulated the extract into a gel using Carbopol 940, methylparaben, triethanolamine, and propylene glycol. We applied the gel to incision wounds in white rats for 7 and 14 days. We then monitored wound healing based on wound length, histology of skin tissues, and levels of cytokine 2 (interleukin-2 [IL-2]). Results: The gel formulation K3 (10% B. balsamifera leaf extract) was the most effective, followed by the gel formulations K2 (5% B. balsamifera leaf extract) and K4 (1% gentamicin ointment, positive control). K3 reduced wound length by 14 mm on day 7 and 29 mm on day 14. Histological analysis showed that fibroblast growth and angiogenesis were most significant in the K3-treated group, exceeding that of the positive control group. The K3-treated group also had the highest IL-2 levels, with an average of 107.7767 ng/L on day 7 and 119.1900 ng/L on day 14. Conclusion: The 10% B. balsamifera leaf gel effectively reduced wound length, increased fibroblast cell growth and angiogenesis, and IL-2 levels, accelerating wound healing.
- Published
- 2022
- Full Text
- View/download PDF
24. Molecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain
- Author
-
Pierre Lemaitre, Samar HK Tareen, Emanuela Pasciuto, Loriana Mascali, Araks Martirosyan, Zsuzsanna Callaerts‐Vegh, Suresh Poovathingal, James Dooley, Matthew G Holt, Lidia Yshii, and Adrian Liston
- Subjects
Aging ,Brain ,Gene Therapy ,Interleukin 2 ,Regulatory T cells ,Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
Abstract Cognitive decline is a common pathological outcome during aging, with an ill‐defined molecular and cellular basis. In recent years, the concept of inflammaging, defined as a low‐grade inflammation increasing with age, has emerged. Infiltrating T cells accumulate in the brain with age and may contribute to the amplification of inflammatory cascades and disruptions to the neurogenic niche observed with age. Recently, a small resident population of regulatory T cells has been identified in the brain, and the capacity of IL2‐mediated expansion of this population to counter neuroinflammatory disease has been demonstrated. Here, we test a brain‐specific IL2 delivery system for the prevention of neurological decline in aging mice. We identify the molecular hallmarks of aging in the brain glial compartments and identify partial restoration of this signature through IL2 treatment. At a behavioral level, brain IL2 delivery prevented the age‐induced defect in spatial learning, without improving the general decline in motor skill or arousal. These results identify immune modulation as a potential path to preserving cognitive function for healthy aging.
- Published
- 2023
- Full Text
- View/download PDF
25. Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG
- Author
-
Dejan Vidovic, Lucy Kathryn Helyer, Sylvia Pasternak, and Carman Anthony Giacomantonio
- Subjects
interleukin 2 ,IL2 ,BCG ,intralesional ,intratumoral ,melanoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Cutaneous melanoma is relatively common with increasing incidence and significant mortality. While the mainstay of therapy is surgical, patients with stage III and IV disease fare poorer than those with early-stage disease and often benefit from adjuvant therapies. While systemic immunotherapy has changed the landscape of melanoma treatment, for some patients systemic toxicities related to these treatments prohibit successful administration or completion of therapy. Moreover, it is becoming increasingly evident that nodal, regional, and in-transit disease appears to be resistant to systemic immunotherapy relative to responses observed in distant metastatic disease sites. In this scenario, intralesional immunotherapies may offer benefit. In this case series, we describe the use of intralesional IL-2 and BCG at our institution in ten patients with in-transit plus or minus distant cutaneous metastatic melanoma over the last twelve years. All patients received intralesional IL2 and BCG. Both treatments were very well tolerated with only grade 1/2 adverse events. In our cohort, complete clinical response was 60% (6/10), progressive disease in 20% (2/10), and no response in 20% (2/10) of patients. The overall response rate (ORR) was 70%. The median overall survival was 35.5 months and mean overall survival 43 months in this cohort. Herein we further highlight the clinical, histopathological, and radiological course of two complete responders, showing evidence of an abscopal effect with resolution of distant untreated metastasis. Together, this limited data supports the safe and effective use of intralesional IL2 and BCG for the treatment of metastatic or in-transit melanoma in this challenging patient cohort. To our knowledge, this is the first formal study to report on this combination therapy for the treatment of melanoma.
- Published
- 2023
- Full Text
- View/download PDF
26. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseasesResearch in context
- Author
-
Miro E. Raeber, Dilara Sahin, Ufuk Karakus, and Onur Boyman
- Subjects
Interleukin 2 ,IL-2 ,Cancer ,Autoimmune disease ,Immunotherapy ,Systematic review ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and regulatory T (Treg) cells. The ability of selectively engaging either of these effects has spurred interest in using IL-2 for immunotherapy of cancer and autoimmune diseases. Thus, numerous IL-2-based biologic agents with improved bias or delivery towards effector immune cells or Treg cells have been developed. This study systematically reviews clinical results of improved IL-2-based compounds. Methods: We searched the ClinicalTrials.gov database for registered trials using improved IL-2-based agents and different databases for available results of these studies. Findings: From 576 registered clinical trials we extracted 36 studies on different improved IL-2-based compounds. Adding another nine agents reported in recent literature reviews and based on our knowledge totalled in 45 compounds. A secondary search for registered clinical trials of each of these 45 compounds resulted in 141 clinical trials included in this review, with 41 trials reporting results. Interpretation: So far, none of the improved IL-2-based compounds has gained regulatory approval for the treatment of cancer or autoimmune diseases. NKTR-214 is the only compound completing phase 3 studies. The PIVOT IO-001 trial testing the combination of NKTR-214 plus Pembrolizumab compared to Pembrolizumab monotherapy in metastatic melanoma missed its primary endpoints. Also the PIVOT-09 study, combining NKTR-214 with Nivolumab compared to Sunitinib or Cabozantinib in advanced renal cell carcinoma, missed its primary endpoint. Trials in autoimmune diseases are currently in early stages, thus not allowing definite conclusions on efficacy. Funding: This work was supported by public funding agencies.
- Published
- 2023
- Full Text
- View/download PDF
27. IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model.
- Author
-
Wang, Xiaoze, Chen, Gang, Nie, Lei, Wu, Zhenhua, Wang, Xinzeng, Pan, Chenxiao, Chen, Xuchen, Zhao, Xiaobei, Zhu, Jie, He, Qiaojun, and Wang, Haibin
- Subjects
- *
INTERLEUKINS , *DRUG efficacy , *BIOLOGICAL models , *IN vitro studies , *IN vivo studies , *GENETIC mutation , *HIGH performance liquid chromatography , *ANIMAL experimentation , *LIQUID chromatography , *ANTINEOPLASTIC agents , *IMMUNOLOGIC receptors , *T-test (Statistics) , *MASS spectrometry , *ENZYME-linked immunosorbent assay , *CELL proliferation , *STATISTICAL hypothesis testing , *TUMORS , *POLYMERASE chain reaction , *DATA analysis software , *IMMUNOTHERAPY , *MICE , *SPECTRUM analysis , *PHARMACODYNAMICS - Abstract
Simple Summary: The application of IL-2 for treating cancer is limited owing to its toxicity and short half-life. Its high binding ability to IL-2 receptor α expands immunosuppressive Treg cells, which represents an undesirable toxicity in cancer immunotherapy. Moreover, its small molecular size is the reason for its short half-life. We solved these problems by using a covalent modification strategy of IL-2 variant IL-2K35C with fatty acid by maleimide chemistry, namely, IL-2K35C-moFA. The experiments performed in vitro and in vivo proved that IL-2K35C-moFA is a novel immunotherapeutic agent with the potential to selectively stimulate CD8+ T cells and NK cells. Compared to IL-2WT, IL-2K35C-moFA showed a specifically reduced potency for the stimulation of Treg cells. Our results also showed that fatty acid conjugation appears to be effective in half-life extension. The combination of selective lymphocyte expansion and its long half-life means IL-2K35C-moFA should be evaluated as a potential human immunotherapeutic in the future. Human interleukin 2 (IL-2) has shown impressive results as a therapeutic agent for cancer. However, IL-2-based cancer therapy is limited by strong Treg amplification owing to its high binding affinity to IL-2 receptor α (IL-2Rα) and its short half-life owing to its small molecular size. In this study, we solved these problems using a covalent modification strategy of the IL-2 variant, i.e., substituting cysteine (C) for lysine (K) at position 35, using octadecanedicarboxylic acid through maleimide chemistry, creating IL-2K35C-moFA. IL-2K35C-moFA was equipotent to human IL-2 wild type (IL-2WT) in activating tumor-killing CD8+ memory effector T cells (CD8+ T) and NK cells bearing the intermediate affinity IL-2 receptors, and less potent than IL-2WT on CTLL-2 cells bearing the high-affinity IL-2 receptors. Moreover, it was shown to support the preferential activation of IL-2 receptor β (IL-2Rβ) over IL-2Rα because of the mutation and fatty acid conjugation. In a B16F10 murine tumor model, IL-2K35C-moFA showed efficacy as a single dose and provided durable immunity for 1 week. Our results support the further evaluation of IL-2K35C-moFA as a novel cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Evaluation of Interleukin 2, Interleukin 10, and Interferon Gamma Among Pregnant Women Co-infected With HIV and Plasmodium falciparum.
- Author
-
Akinbo, Frederick O., Abiodun, Florence Oluyemi, Omoregie, Richard, Omoruyi, Zainab, and Oriakhi, Mathew O.
- Subjects
- *
INTERFERON gamma , *PREGNANT women , *PLASMODIUM falciparum , *HIV , *MARITAL status - Abstract
Background: In pregnancy, the body undergoes modulation of pro-inflammation responses to ensure fetal survival, and these adjustments may decrease maternal immune defenses and promote infections. Objectives: This study was conducted to determine interleukin 2 (IL-2), IL-10, and interferon gamma (IFN-γ) among pregnant women co-infected with HIV and Plasmodium falciparum in Edo State, Nigeria. Methods: This study was conducted at the Central Hospital, Benin City, Edo State. A total of 200 participants were enrolled, consisting of 150 pregnant women co-infected with HIV and P. falciparum and 50 non-pregnant women (as controls) who were neither infected with HIV nor P. falciparum. Venous blood specimen was collected for P. falciparum detection, CD4 T-lymphocyte estimation, and IL-2, IL-10, and IFN-assays using standard methods. Results: Among HIV-infected pregnant women, IL-2 (P = 0.0070), IL-10 (P = 0.0179) and IFN-γ (P = 0.1564) values were lower in primiparous women compared with multiparous women. HIV-infected pregnant women who were married had significantly higher IL-2 (P = 0.0085) and IFN-γ levels (P = 0.0332) compared with single women, while marital status did not affect the IL-10 level of pregnant women infected with HIV. Only the IL-2 levels of the HIV-infected pregnant women increased significantly (P = 0.0012) with increasing trimester. The tested cytokine levels were lower in those with malaria compared with those withoutmalariaamongHIV-infected pregnant women. Conclusions: The HIV status and not malaria infection affects the cytokine levels of pregnant women co-infected with HIV and malaria. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy.
- Author
-
Tong, Bei, Leong, Sirou Grace, Jian, Tunyu, Niu, Guanting, Gai, Yanan, Meng, Xiuhua, Lv, Han, Dong, Xianchi, Ding, Xiaoqin, and Chen, Jian
- Subjects
- *
REGULATORY T cells , *T cells , *IMMUNOTHERAPY , *KILLER cells , *CANCER treatment , *CD25 antigen - Abstract
• PEGylation is advantageous for extending the in vivo half-life of IL2. • Constructing IL2 mutant to impart a bias towards inducing effector T cells. • EC50 ratio of Mo7e and CTLL-2 cells is an indicator for immunotherapy evaluation. While Interleukin 2 (IL2) has the capability to activate both NK and T cells robustly, its limited in vivo half-life, considerable toxicity, and tendency to boost Treg cells pose significant challenges, restricting its widespread application in cancer therapy. In this investigation, we engineered a novel IL2 variant (IL2-4M-PEG) with reduced CD25 binding activity and an extended half-life by substituting amino acids associated with CD25 binding and implementing site-directed PEGylation. IL2-4M-PEG notably amplifies effector cells over Treg cells. Furthermore, our findings reveal that IL2-4M-PEG, characterized by an extended half-life, exhibits anti-tumor effects in a mouse model. Consequently, this innovative IL2 holds the potential for enhancing combined cancer therapies in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Long-term effect of childhood trauma: Role of inflammation and white matter in mood disorders
- Author
-
Sara Poletti, Marco Paolini, Julia Ernst, Irene Bollettini, Elisa Melloni, Benedetta Vai, Yasmin Harrington, Beatrice Bravi, Federico Calesella, Cristina Lorenzi, Raffaella Zanardi, and Francesco Benedetti
- Subjects
Interleukin 2 ,Bipolar disorder ,Early stress ,White matter ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Bipolar disorder (BD) and major depressive disorder (MDD) are severe psychiatric illnesses that share among their environmental risk factors the exposure to adverse childhood experiences (ACE). Exposure to ACE has been associated with long-term changes in brain structure and the immune response. In the lasts decades, brain abnormalities including alterations of white matter (WM) microstructure and higher levels of peripheral immune/inflammatory markers have been reported in BD and MDD and an association between inflammation and WM microstructure has been shown. However, differences in these measures have been reported by comparing the two diagnostic groups. The aim of the present study was to investigate the interplay between ACE, inflammation, and WM in BD and MDD. We hypothesize that inflammation will mediate the association between ACE and WM and that this will be different in the two groups. A sample of 200 patients (100 BD, 100 MDD) underwent 3T MRI scan and ACE assessment through Childhood Trauma Questionnaire. A subgroup of 130 patients (75 MDD and 55 BD) underwent blood sampling for the assessment of immune/inflammatory markers. We observed that ACE associated with higher peripheral levels of IL-2, IL-17, bFGF, IFN-γ, TNF-α, CCL3, CCL4, CCL5, and PDGF-BB only in the BD group. Further, higher levels of CCL3 and IL-2 associated with lower FA in BD. ACE were found to differently affect WM microstructure in the two diagnostic groups and to be negatively associated with FA and AD in BD patients. Mediation analyses showed a significant indirect effect of ACE on WM microstructure mediated by IL-2. Our findings suggest that inflammation may mediate the detrimental effect of early experiences on brain structure and different mechanisms underlying brain alterations in BD and MDD.
- Published
- 2022
- Full Text
- View/download PDF
31. Dynamics of Mycobacterium tuberculosis-Specific and Nonspecific Immune Responses in Women with Tuberculosis Infection during Pregnancy
- Author
-
Fregenet Tesfaye, Erik Sturegård, John Walles, Bayissa Bekele, Kidist Bobosha, Per Björkman, and Marianne Jansson
- Subjects
tuberculosis infection ,pregnancy ,Mycobacterium tuberculosis antigen reactivity ,HIV-uninfected ,interleukin 2 ,interferon-γ inducible protein 10 ,Microbiology ,QR1-502 - Abstract
ABSTRACT The immune control of tuberculosis (TB) infection could be influenced by pregnancy. To elucidate this, we longitudinally characterized Mycobacterium tuberculosis (Mtb)-specific and nonspecific immune responses in women during pregnancy and postpartum. HIV-uninfected women without past or current active TB, and with blood samples available from the 1st/2nd trimester, 3rd trimester, and 9 months postpartum, were identified at Ethiopian antenatal care clinics. Twenty-two TB+ women and 10 TB− women, defined according to Mtb-stimulated interferon-γ levels (≥0.35 and
- Published
- 2022
- Full Text
- View/download PDF
32. The ADP-Ribosylation Factor 4d Restricts Regulatory T-Cell Induction via Control of IL-2 Availability.
- Author
-
Geers, Bernd, Hagenstein, Julia, Endig, Jessica, Ulrich, Hanna, Fleig, Laura, Sprezyna, Paulina, Mikulec, Julita, Heukamp, Lukas, Tiegs, Gisa, and Diehl, Linda
- Subjects
- *
REGULATORY T cells , *ADP-ribosylation , *INTERLEUKIN-2 , *T cells , *CD4 antigen - Abstract
Interleukin-2 is central to the induction and maintenance of both natural (nTreg) and induced Foxp3-expressing regulatory T cells (iTreg). Thus, signals that modulate IL-2 availability may, in turn, also influence Treg homeostasis. Using global knockout and cell-specific knockout mouse models, we evaluated the role of the small GTPase ADP-ribosylation factor 4d (Arl4d) in regulatory T-cell biology. We show that the expression of Arl4d in T cells restricts both IL-2 production and responsiveness to IL-2, as measured by the phosphorylation of STAT5. Arl4d-deficient CD4 T cells converted more efficiently into Foxp3+ iTreg in vitro in the presence of αCD3ε and TGFβ, which was associated with their enhanced IL-2 secretion. As such, Arl4d−/− CD4 T cells induced significantly less colonic inflammation and lymphocytic infiltration in a model of transfer colitis. Thus, our data reveal a negative regulatory role for Arl4d in CD4 T-cell biology, limiting iTreg conversion via the restriction of IL-2 production, leading to reduced induction of Treg from conventional CD4 T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Protective effects of pentoxifylline on T-cell viability under inflammatory conditions.
- Author
-
Park, Sung-Joon, Choi, Sung-Hyuk, Cho, Young-Duck, Kim, Jung-Youn, Cho, Han-Jin, Kim, Kyung-Hwan, and Kim, Won-Young
- Subjects
- *
MACROPHAGE migration inhibitory factor , *PENTOXIFYLLINE , *T cells - Abstract
Introduction: Pentoxifylline (PTX) reduces the levels of pro-inflammatory cytokines; however, its effects on immune system is not well understood. The aim of this study was to investigate the effect of PTX on T cells under inflammatory conditions in co-culture with THP-1-derived macrophages. Methods: Toll-like receptor 4 (TLR4) and macrophage migration inhibitory factor (MIF) levels were measured after addition of PTX to lipopolysaccharide (LPS)-stimulated differentiated THP-1 cells. T cell viability and MIF levels were measured after PTX was added to prostaglandin E2 (PGE2)-stimulated Jurkat T-cell leukemia line. Co-culture was conducted to determine the effect of LPS-stimulated differentiated THP-1 cells that are affected by PTX on Jurkat cells. To prevent the direct effects of LPS and PTX on Jurkat cells, LPS and PTX were washed from THP-1 cells before co-culture. T cell viability and interleukin-2 (IL-2) levels were determined in Jurkat cells. Results: Increase in the MIF concentration and TLR4 expression level in differentiated THP-1 cells stimulated with LPS were reversed after PTX addition. However, PTX did not improve T cell viability in PGE2–stimulated Jurkat cells. Co-culturing Jurkat cell and LPS-stimulated differentiated THP-1 cells resulted in a decreased viability of T cells. The addition of PTX restored T cell viability to normal control levels and IL-2 expression level in Jurkat cells. Conclusion: LPS-stimulated THP-1-derived macrophages reduced the T cell viability under inflammation. However, PTX restored T cells viability and IL-2 back to normal levels. Therefore, the immunomodulatory action of PTX may be mediated by macrophage-T cell interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Immunological indices of Giant African Land snails (Archachatina marginata) improved with fixed dose of vitamin C during acute heat stress
- Author
-
Odinaka Christian Iwuozo, John Adesanya Abiona, Monsuru Oladimeji Abioja, and Babatunde Moses Ilori
- Subjects
exposure time ,immunological cytokines ,interferon gamma ,interleukin 2 ,total haemocytes counts ,land snails. ,Animal culture ,SF1-1100 - Abstract
The study determined immunological indices of Giant African Land snail (Archachatina marginata) improved with fixed dose of vitamin C under acute heat stress (AHS). Prior to the AHS, vitamin C was administered for four weeks to two treatment groups, while other two treatment groups were not. Each treatment was monitored, haemolymph collected at 0, 30 and 60 minutes exposure times. Immunological cytokines: interferon gamma (IFN-γ) and interleukin 2 (IL-2); and total haemocyte counts (THC) were determined. Under AHS, vitamin C elevated (p 0.05) by vitamin C under AHS. Highest (p 0.05). With fixed dose of vitamin C and exposure time, highest (p
- Published
- 2022
- Full Text
- View/download PDF
35. T-cell responses to SARS-CoV-2 in unexposed South African women [version 2; peer review: 2 approved]
- Author
-
Marta C. Nunes, Gaurav Kwatra, Michael J. Johnson, Shabir A. Madhi, and Adriana Weinberg
- Subjects
cell mediated immunity ,SARS-CoV-2 ,interferon gamma ,interleukin 2 ,eng ,Medicine - Abstract
Background: A potential explanation for the fact that the high rate of infection of SARS-CoV-2 in South Africa did not translate into high rates of severe illness and death may be the presence of cross-reactive immunity induced by common cold coronaviruses (CCoV). Methods: We used SARS-CoV-2 peptide pools and whole virus antigen to stimulate peripheral blood mononuclear cells collected pre-2020 from South African women. Dual-colour FluoroSpot assay was used to measure interferon gamma (IFNγ) and interleukin 2 (IL2) production. Results: Among the 97 study participants, IFNγ responses were observed in 29.9% of the women and IL2 among 39.2%. Overall, 51.6% of women demonstrated response to at least one stimulant. Conclusion: We demonstrate the presence of cross-reactive immunity to SARS-CoV-2, which might have been induced by past exposure to CCoV.
- Published
- 2022
- Full Text
- View/download PDF
36. Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection.
- Author
-
Zhang, Jia-Qian, Zhang, Sheng-Xiao, Wang, Jia, Qiao, Jun, Qiu, Meng-Ting, Wu, Xiao-Yan, Chen, Jun-Wen, Gao, Chong, and Li, Xiao-Feng
- Subjects
- *
SYSTEMIC lupus erythematosus , *LYMPHOCYTE subsets , *REGULATORY T cells , *KILLER cells , *HOMEOSTASIS , *AUTOIMMUNE diseases , *LYMPHOCYTE count - Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by disturbed cellular and humoral immune responses. Dysregulations of immune system and immunosuppressive medications predispose SLE patients to infection. This study aims to investigate the alterations and absolute concentrations of lymphocyte subpopulations in SLE patients with different infection and their responses of low-dose IL-2 therapy. A total of 333 patients with SLE without recent infection, 162 patients suffering infection, and age and sex-matched 132 healthy controls (HCs) were recruited. Of them, 54 SLE patients (including 41 non-infected group and 13 infected group) received a 5-day course of low-dose IL-2 administration at a dose of 0.5 million IU per day. Lymphocyte subpopulations were analyzed by flow cytometry. Patients with SLE had lower levels of lymphocyte subpopulations in peripheral blood such as T, B, NK, CD4 + T, CD8+ T, Th1, Th2, Th17, and Treg cells, and the reduction in these cells was more obvious in patients with infection (p <.05 to p <.01). Low-dose IL-2 effectively expanded T (p <.001), B (p <.001), CD4 + T (p <.01), CD8 + T (p <.001), Th1 (p <.01), Th17 (p <.1), and Treg cells (p <.01) of SLE patients, these cells were comparable to that of HCs after the IL-2 treatment. Patients with SLE had insufficiency of circulating lymphocyte subsets. This phenomenon was more obverse in those accompanying infection, suggesting the low concentration of lymphocytes may be used as indicators of high infection risk in SLE patients. Low-dose IL-2 induced expansion of Treg cells and NK cells, which may contribute to the restoration of immune homeostasis in SLE patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists.
- Author
-
Deligiorgi, Maria V. and Trafalis, Dimitrios T.
- Subjects
CONTINUUM of care ,HYPOTHYROIDISM ,ENDOCRINOLOGISTS ,IMMUNE checkpoint inhibitors ,PROTEIN-tyrosine kinase inhibitors ,THYROID hormone receptors ,DOSE-response relationship (Radiation) ,THYROID hormone regulation - Abstract
Hypothyroidism is a common adverse event of various anticancer treatment modalities, constituting a notable paradigm of the integration of the endocrine perspective into precision oncology. The present narrative review provides a comprehensive and updated overview of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors. A study search was conducted on the following electronic databases: PubMed, Google Scholar, Scopus.com, ClinicalTrials.gov, and European Union Clinical Trials Register from 2011 until August 2021. In patients with solid non-thyroid tumors, hypothyroidism is a common adverse event of radiotherapy, high-dose interleukin 2 (HD IL-2), interferon alpha (IFN-α), bexarotene, immune checkpoint inhibitors (ICPi), and tyrosine kinase inhibitors (TKIs), while chemotherapy may induce hypothyroidism more often than initially considered. The path forward for the management of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors is an integrated approach grounded on five pillars: prevention, vigilance, diagnosis, treatment, and monitoring. Current challenges concerning anticancer treatment-induced hypothyroidism await counteraction, namely awareness of the growing list of related anticancer treatments, identification of predictive factors, counteraction of diagnostic pitfalls, tuning of thyroid hormone replacement, and elucidation of its prognostic significance. Close collaboration of oncologists with endocrinologists will provide optimal patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
38. Administration of fusion cytokines induces tumor regression and systemic antitumor immunity
- Author
-
Jinyu Zhang and Xuan Zhao
- Subjects
cancer immunotherapy ,fusion cytokine ,immunocytokine ,interleukin 12 ,interleukin 2 ,granulocyte macrophage colony stimulating factor ,Medicine - Abstract
Abstract It is difficult to improve the curative effects of cancer immunotherapy on solid tumors. Cytokines, as powerful immune regulators, show potential in activating host antitumor immunity. We have previously found that the administration of certain cytokine combinations induces complete tumor clearance. Here, we constructed cognate fusion cytokines and evaluated their antitumor effects in various mouse tumor models. The in situ induction of the expression of the fusion cytokine IL12IL2GMCSF caused tumor eradication, including that of the tumors at advanced stages. An immune memory against unrelated syngeneic tumors was also elicited. Furthermore, flow cytometry analysis revealed that tumor‐infiltrating CD3+ cells were greatly increased in the treated tumors and were accompanied by an elevation of CD8+/CD4+ ratios. This fusion protein exhibited superior immune activating capability compared to that of cytokine mixtures, in the experiments done in vitro. We also induced tumor regression in various immunocompetent tumor models via intratumoral injection. To improve its translational potential for clinical application, a systemically‐administered immunocytokine, IL12IL2DiaNFGMCSF, was constructed by inserting a tumor‐targeting diabody in the fusion protein. This protein also displayed good immune stimulating activities in vitro. Intravenous infusion of IL12IL2DiaNFGMCSF induced tumor‐infiltrating immune cell alterations like IL12IL2GMCSF, with moderate serum IFNγ increment. Therapeutic effects were observed in the various tumor models after systemic administration of IL12IL2DiaNFGMCSF, but with slight toxicity. These results show the feasibility of developing a versatile cancer immunotherapy.
- Published
- 2021
- Full Text
- View/download PDF
39. Effect of low dose IL-2 loaded chitosan nanoparticles on natural killer and regulatory T cell expression in experimentally induced autoimmune type 1 diabetes mellitus
- Author
-
Salma Aboelnazar, Hossam Ghoneim, Thanaa Shalaby, Eman Bahgat, and Mai Moaaz
- Subjects
streptozotocin ,natural killer ,t-regulatory ,interleukin 2 ,balb/c mice. ,Medicine - Published
- 2021
- Full Text
- View/download PDF
40. Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study (NIL-2 pilote)
- Published
- 2018
41. The role of cAMP dependent gene transcription in lupus pathophysiology.
- Author
-
Thomas, Rauen and Klaus, Tenbrock
- Subjects
- *
PATHOLOGICAL physiology , *SYSTEMIC lupus erythematosus , *GENETIC regulation , *GENE expression , *CELLULAR signal transduction , *T cells , *CD28 antigen - Abstract
T lymphocytes play a major role in the pathophysiology of systemic lupus erythematosus. T cellular dysregulation includes significant alterations in signal transduction, cytokine production and metabolic pathways. The cAMP dependent transcription factors like CREB and CREM exert pleiotropic functions as they are critically involved in epigenetic conformational changes and gene regulation of different key effector cytokines in CD4+ T cells including that of IL2 , IL17 and IL21 genes. In the present review we review current knowledge on altered expression and function of these factors in T cells that promote autoimmunity in SLE patients. • T lymphocytes play a major role in the pathophysiology of systemic lupus erythematosus • T cellular dysregulation includes significant alterations in signal transduction, cytokine production and metabolic pathways • The cAMP dependent transcription factors like CREB and CREM exert pleiotropic functions as they are critically involved in epigenetic conformational changes and gene regulation of different key effector cytokines in CD4+ T cells including that of IL2 , IL17 and IL21 genes • In the present review we review current knowledge on altered expression and function of these factors in T cells that promote autoimmunity in SLE patients and will highlight the contribution of George Tsokos and his group. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Protective effects of pentoxifylline on T-cell viability under inflammatory conditions.
- Author
-
Sung-Joon Park, Sung-Hyuk Choi, Young-Duck Cho, Jung-Youn Kim, Han-Jin Cho, Kyung-Hwan Kim, and Won-Young Kim
- Subjects
- *
MACROPHAGE migration inhibitory factor , *PENTOXIFYLLINE , *T cells - Abstract
Introduction: Pentoxifylline (PTX) reduces the levels of pro-inflammatory cytokines; however, its effects on immune system is not well understood. The aim of this study was to investigate the effect of PTX on T cells under inflammatory conditions in co-culture with THP-1-derived macrophages. Methods: Toll-like receptor 4 (TLR4) and macrophage migration inhibitory factor (MIF) levels were measured after addition of PTX to lipopolysaccharide (LPS)-stimulated differentiated THP-1 cells. T cell viability and MIF levels were measured after PTX was added to prostaglandin E2 (PGE2)-stimulated Jurkat T-cell leukemia line. Co-culture was conducted to determine the effect of LPS-stimulated differentiated THP-1 cells that are affected by PTX on Jurkat cells. To prevent the direct effects of LPS and PTX on Jurkat cells, LPS and PTX were washed from THP-1 cells before co-culture. T cell viability and interleukin-2 (IL-2) levels were determined in Jurkat cells. Results: Increase in the MIF concentration and TLR4 expression level in differentiated THP-1 cells stimulated with LPS were reversed after PTX addition. However, PTX did not improve T cell viability in PGE2-stimulated Jurkat cells. Co-culturing Jurkat cell and LPS-stimulated differentiated THP-1 cells resulted in a decreased viability of T cells. The addition of PTX restored T cell viability to normal control levels and IL-2 expression level in Jurkat cells. Conclusion: LPS-stimulated THP-1-derived macrophages reduced the T cell viability under inflammation. However, PTX restored T cells viability and IL-2 back to normal levels. Therefore, the immunomodulatory action of PTX may be mediated by macrophage-T cell interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. Immunological indices of Giant African Land snails (Archachatina marginata) improved with fixed dose of vitamin C during acute heat stress.
- Author
-
Christian Iwuozo, Odinaka, Adesanya Abiona, John, Oladimeji Abioja, Monsuru, and Moses Ilori, Babatunde
- Abstract
The study determined immunological indices of Giant African Land snail (Archachatina marginata) improved with fixed dose of vitamin C under acute heat stress (AHS). Prior to the AHS, vitamin C was administered for four weeks to two treatment groups, while other two treatment groups were not. Each treatment was monitored, haemolymph collected at 0, 30 and 60 minutes exposure times. Immunological cytokines: interferon gamma (IFN-γ) and interleukin 2 (IL-2); and total haemocyte counts (THC) were determined. Under AHS, vitamin C elevated (p <0.05) IFN-γ production (606.33 ± 302.86) compared to other groups with or without vitamin C administration (7.20 ± 1.58 vs. 73.20 ± 32.23 vs. 7.80 ± 1.36). IL-2 was not affected (p >0.05) by vitamin C under AHS. Highest (p <0.05) THC values was obtained with vitamin C administration under AHS, but reduced under no AHS. Exposure time affected (p <0.05) IFN-γ production and THC values, but not IL-2 (p >0.05). With fixed dose of vitamin C and exposure time, highest (p <0.05) IFN-γ values were obtained under AHS with vitamin C administration at 30 minutes and at 60 minutes in THC, compared to other groups. The study concluded that fixed dose of vitamin C at 150 mg kg
-1 of feed was appropriate under AHS to boost the immune system of the animals. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
44. Melanoma Immunology and Immunotherapy
- Author
-
Sullivan, Ryan J., Hodi, F. Stephen, Fisher, David E., Section editor, Hayward, Nick, Section editor, Whiteman, David C., Section editor, Flaherty, Keith T., Section editor, Tsao, Hensin, Section editor, Merlino, Glenn, Section editor, Fisher, David E., editor, and Bastian, Boris C., editor
- Published
- 2019
- Full Text
- View/download PDF
45. The cAMP responsive element modulator (CREM) is a regulator of CD4+ T cell function.
- Author
-
Subramanyam, Sudheendra Hebbar and Tenbrock, Klaus
- Subjects
- *
CELL physiology , *T helper cells , *T cells , *SYSTEMIC lupus erythematosus , *INTERLEUKIN-17 , *AUTOIMMUNE diseases - Abstract
The cAMP responsive element modulator (CREM) is a transcriptional regulator of different effector cytokines in CD4+ T cells including IL-2, IL-17, IL-21 but also IL-4 and IL-13 and thus an important determinant of central T helper cell functions. Our review gives an overview over the regulation of CREM in T cells and the pleiotropic effects of CREM on CD4+ T cells in health and autoimmune diseases with a particular focus on systemic lupus erythematosus. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma
- Author
-
Brian K. Flesner, Gary W. Wood, Pamela Gayheart‐Walsten, F. Lynn Sonderegger, Carolyn J. Henry, Deborah J. Tate, Sandra M. Bechtel, Lindsay L. Donnelly, Gayle C. Johnson, Dae Young Kim, Tammie A. Wahaus, Jeffrey N. Bryan, and Noe Reyes
- Subjects
canine ,immunotherapy ,interleukin 2 ,leukapheresis ,osteosarcoma ,Veterinary medicine ,SF600-1100 - Abstract
Abstract Background Osteosarcoma (OSA) in dogs is an aggressive bone tumor with frequent chemotherapy failure and translational relevance for human health. Hypothesis/Objectives We hypothesized that dogs with OSA could be treated safely by ex vivo activated T‐cells that were generated by autologous cancer vaccination and supported by interleukin‐2 (IL‐2) treatment with survival more than twice that reported for amputation alone. Animals Osteosarcoma‐bearing dogs (n = 14) were enrolled in a single‐arm prospective trial after complete staging before amputation. Four healthy dogs also were treated in a safety study. Methods Autologous cancer cell vaccinations were administered intradermally and dogs underwent leukapheresis. Mononuclear cell products were stimulated ex vivo with a T‐cell‐activating agent. Activated product was transfused and 5 SC IL‐2 injections were administered q48h. Dogs were monitored for metastasis by thoracic radiography every 3 months. Results Autologous cancer cell vaccine and activated cellular therapy (ACT) products were successfully generated. Toxicity was minimal after premedicants were instituted before ACT. With premedication, all toxicities were grade I/II. Median disease‐free interval for all dogs was 213 days. One dog developed cutaneous metastasis but then experienced spontaneous complete remission. Median survival time for all dogs was 415 days. Five dogs survived >730 days. Conclusions and Clinical Importance This immunotherapy protocol without cytotoxic chemotherapy is safe and tolerable. Compared to historical amputation reports, survival was notably prolonged in this group of patients. Additional prospective studies are warranted to elucidate active immunologic mechanisms and further improve disease response and survival.
- Published
- 2020
- Full Text
- View/download PDF
47. Recovery of T‐cell function in healthy dogs following cessation of oral cyclosporine administration
- Author
-
Lakshmi Narayanan, Charlee Mulligan, Lisa Durso, Brittany Thames, John Thomason, Claire Fellman, Andrew Mackin, Robert Wills, and Todd Archer
- Subjects
cyclosporine ,cytokines ,interferon gamma ,interleukin 2 ,T cell ,Veterinary medicine ,SF600-1100 - Abstract
Abstract Cyclosporine is a potent immunosuppressive agent used to treat immune‐mediated disorders in dogs. Secondary infections sometimes necessitate withdrawal of cyclosporine, but it is not known how long it takes for the immune system to recover after cessation of cyclosporine. Our goal was to utilize a validated RT‐qPCR assay in dogs to assess recovery time of the T‐cell cytokines IL‐2 and IFN‐γ after discontinuation of cyclosporine. Six healthy dogs were given oral cyclosporine (10 mg/kg every 12 hr) for 1 week, with samples collected for measurement of cytokine gene expression prior to treatment, and on the last day of therapy. Cyclosporine was then discontinued, and samples were collected daily for an additional 7 days. Results revealed that there was a significant difference in cytokine expression when comparing pre‐treatment and immediate post‐treatment values, corresponding to marked suppression of T‐cell function. There was no significant difference between pre‐treatment values for either cytokine when compared with any day during the recovery period. Cytokine expression, evaluated as a percentage of pre‐treatment baseline samples, demonstrated progressing return of T‐cell function after drug cessation, with full recovery seen in all dogs by Day 4 of the recovery period.
- Published
- 2020
- Full Text
- View/download PDF
48. Association of interleukin 2, interleukin 12, and interferon-γ with intervertebral disc degeneration in Iranian population
- Author
-
Sara Hanaei, Sina Abdollahzade, Maryam Sadr, Mohammad Hossein Mirbolouk, Ehsan Fattahi, Alireza Khoshnevisan, and Nima Rezaei
- Subjects
Intervertebral disc degeneration ,Single nucleotide polymorphism ,Interleukin 2 ,Interleukin 12 ,Interferon γ ,Immunogenetics ,Internal medicine ,RC31-1245 ,Genetics ,QH426-470 - Abstract
Abstract Background Intervertebral disc degeneration (IVDD) is an age-related degenerative disease, presenting with low back pain or radicular pain. The inflammatory changes would occur in discs in the process of IVDD. Therefore, the inflammatory and anti-inflammatory cytokines, as well as their respective genes, have been proposed to play roles in pathophysiology of disease. This study has been conducted to elucidate the role of IL-2, IL-12, and IFN-γ single nucleotide polymorphisms (SNP) in this disease. Method Seventy-six patients who were diagnosed with IVDD and 140 healthy controls who complied with eligibility criteria were included. A total volume of 5 cc peripheral blood was obtained from each participant to investigate the IL-2 + 166G/T, IL-2 -330G/T, IL-12 − 1188A/C, and IFN-γ +847A/T SNPs through PCR-SSP method. Results The ‘TG’ and ‘TT’ genotypes of IL-2 − 330G/T polymorphism were significantly more common among patients and healthy controls respectively. The ‘GT’ and ‘TT’ haplotypes of IL-2 (comprised of -330G/T, and + 166G/T SNPs) were also more common among patients and controls respectively. Conclusion This study indicated the significant role of IL-2 genotypes and haplotypes in IVDD. These SNPs were differently distributed in patients and controls. Therefore, alteration in the structure of IL-2 gene could play an important role in pathophysiology of IVDD.
- Published
- 2020
- Full Text
- View/download PDF
49. Effects of oral administration of 5 immunosuppressive agents on activated T‐cell cytokine expression in healthy dogs
- Author
-
Todd M. Archer, Charlee Mulligan, Lakshmi Narayanan, Caitlin Riggs, Claire Fellman, John M. Thomason, Robert W. Wills, Dawn M. Boothe, Crisanta Cruz‐Espindola, Roy Harmon, and Andrew J. Mackin
- Subjects
azathioprine ,cyclosporine ,interferon gamma ,interleukin 2 ,leflunomide ,mycophenolate mofetil ,Veterinary medicine ,SF600-1100 - Abstract
Abstract Background Dogs are often adminstered >1 immunosuppressive medication when treating immune‐mediated diseases, and determining whether these different medications affect IL‐2 expression would be useful when performing pharmacodynamic monitoring during cyclosporine therapy. Hypothesis/Objectives To determine the effects of 5 medications (prednisone, cyclosporine, azathioprine, mycophenolate mofetil, and leflunomide) on activated T‐cell expression of the cytokines IL‐2 and interferon‐gamma (IFN‐γ). Animals Eight healthy dogs. Methods Randomized, cross‐over study comparing values before and after treatment, and comparing values after treatment among drugs. Dogs were administered each drug at standard oral doses for 1 week, with a washout of at least 21 days. Activated T‐cell expression of IL‐2 and IFN‐γ mRNA was measured by quantitative reverse transcription polymerase chain reaction. Blood drug concentrations were measured for cyclosporine, mycophenolate, and leflunomide metabolites. Results Least squares means (with 95% confidence interval) before treatment for IL‐2 (2.91 [2.32‐3.50] ΔCt) and IFN‐γ (2.33 [1.66‐3.00 ΔCt]) values were significantly lower (both P
- Published
- 2020
- Full Text
- View/download PDF
50. Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives.
- Author
-
Ikegawa, Shuntaro and Matsuoka, Ken-ichi
- Subjects
REGULATORY T cells ,HEMATOPOIETIC stem cell transplantation ,HOMEOSTASIS ,IMMUNE checkpoint inhibitors ,IMMUNOSUPPRESSION ,LYMPHOPENIA - Abstract
CD4
+ CD25+ Foxp3+ regulatory T cells (Tregs) are functionally distinct subsets of mature T cells with broad suppressive activity and have been shown to play an important role in the establishment of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT). Tregs exhibit an activated phenotype from the stage of emigration from the thymus and maintain continuous proliferation in the periphery. The distinctive feature in homeostasis enables Tregs to respond sensitively to small environmental changes and exert necessary and sufficient immune suppression; however, on the other hand, it also predisposes Tregs to be susceptible to apoptosis in the inflammatory condition post-transplant. Our studies have attempted to define the intrinsic and extrinsic factors affecting Treg homeostasis from the acute to chronic phases after allogeneic HSCT. We have found that altered cytokine environment in the prolonged post-HSCT lymphopenia or peri-transplant use of immune checkpoint inhibitors could hamper Treg reconstitution, leading to refractory graft- versus -host disease. Using murine models and clinical trials, we have also demonstrated that proper intervention with low-dose interleukin-2 or post-transplant cyclophosphamide could restore Treg homeostasis and further amplify the suppressive function after HSCT. The purpose of this review is to reconsider the distinctive characteristics of post-transplant Treg homeostasis and discuss how to harness Treg homeostasis to optimize posttransplant immunity for developing a safe and efficient therapeutic strategy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.